Search
shopping
Search
Menu

Goal and Learning Outcomes

The goal of this program is to familiarize healthcare providers with all classes of antiretroviral medications and how active antiretroviral therapy has affected morbidity and mortality associated with HIV infection. After studying the information presented here, you will be able to:
  • Describe how the prophylaxis of key opportunistic infections and the use of antiretroviral agents introduced since 1996 have affected the trajectory and outcomes of HIV disease treatment
  • Discuss two categories of patients with HIV who continue to be at risk for opportunistic infections and for progression to AIDS
  • List at least four classes of current antiretroviral medications and possible adverse effects patients may experience when taking these medications.
 

 
Christine A Balt, DNP, FNP-BC, AACRN has disclosed she has received speaking fees from Gilead Sciences and ViiV Healthcare.
 

 

Course Authors

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.